Julian R Molina

Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth.

Claude Deschamps, Atique U. Ahmed, Ping Yang, 2008, Journal of the National Cancer Institute.

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).

S. Weroha, J. Molina, T. Reungwetwattana, 2012, Clinical lung cancer.

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Steven E Schild, Ping Yang, Ping Yang, 2008, Mayo Clinic proceedings.

Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.

J. Molina, Julian R Molina, 2008, IDrugs : the investigational drugs journal.

A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes.

Wei-Guo Zhu, Christoph Plass, Yue-zhong Wu, 2003, Human molecular genetics.

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Xin Wang, Fang Yang, Shouhao Zhou, 2019, JAMA oncology.

Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002.

Ping Yang, Jason A Wampfler, J. Jett, 2004, The Annals of thoracic surgery.